Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Amortization of Deferred Charges (2022 - 2025)

Cytokinetics (CYTK) has disclosed Amortization of Deferred Charges for 4 consecutive years, with $14.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Amortization of Deferred Charges changed N/A to $14.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $24.5 million, a N/A change, with the full-year FY2025 number at $22.9 million, up 98.12% from a year prior.
  • Amortization of Deferred Charges was $14.9 million for Q4 2025 at Cytokinetics, up from $3.5 million in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $14.9 million in Q4 2025 to a low of -$13.6 million in Q4 2023.
  • A 4-year average of $3.0 million and a median of $2.7 million in 2024 define the central range for Amortization of Deferred Charges.
  • Biggest YoY gain for Amortization of Deferred Charges was 429.85% in 2023; the steepest drop was 1350.83% in 2023.
  • Cytokinetics' Amortization of Deferred Charges stood at $1.1 million in 2022, then tumbled by 1350.83% to -$13.6 million in 2023, then soared by 125.62% to $3.5 million in 2024, then surged by 326.68% to $14.9 million in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Amortization of Deferred Charges are $14.9 million (Q4 2025), $3.5 million (Q1 2025), and $3.5 million (Q3 2024).